HIGHLIGHTS
SUMMARY
Meanwhile, different classification approaches, such as IHC and gene_expression profiling, for DLBCL patients` assessment raised the question about the differences in accuracy. Studies that compared IHC algorithms and gene_expression profiling revealed a satisfactory level of consistency of both methods for the DLBCL subtyping, but not for drug susceptibility and prognosis prediction. Consequently, recent advanced methods are aimed at subclassifying DLBCL tumor cells into subgroups based on the mutations and signaling pathways that drive DLBCL tumor cells. Recent emerging pieces of evidence highlight that the combination of the international prognostic index (IPI) scores with gene_expression . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.